Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
Key facts
- Who runs it
- St. Joseph's Healthcare Hamilton
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 12 people enrolled
- Started
- 26 Mar 2024
- Ended
- 17 Apr 2025
- Type of study
- Interventional
- Treatments tested
- dTMS stimulation via the H4 coil
- Record updated
- 30 March 2026
Who can take part
- Age
- 25 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Adult, age 25-65
- DSM-5 CUD, moderate or higher (4+ DSM-5 symptoms)
- 4 or more days of cannabis use per week
- Reports inhalation as one route of administration
- Treatment-seeking (i.e., self-reported readiness to change of 5 or greater on a 0-10 readiness ruler)
- Stable domicile and reliable transportation, and willingness to attend in-person visits at SJHH Hamilton
Who cannot take part
- Co-enrollment in a clinical drug trial
- Current psychotic symptoms, history of schizophrenia-spectrum disorders or bipolar disorder, or current PTSD
- Active suicidality (past 3 months) or history of severe suicidality (i.e., requiring hospitalization)
- Any other mental health condition deemed incompatible by the team
- High risk alcohol involvement and/or 4+ symptoms of alcohol use disorder
- Unstable management of an existing mental health condition or anticipation of a change to the treatment over the next 3 months
- Current unstable medical condition (e.g., diabetes)
- rTMS Contraindications: intracranial or metal implants in the head or nearby regions that cannot be safely removed; history of epilepsy or seizures; pregnancy (female participants only); pacemaker and/or implantable cardioverter-defibrillators)
- Medication contraindications (e.g., bupropion >300 mg/day due to risk of seizures, benzodiazepine equivalent dose to lorazepam >2 mg/day)
- History of recurrent headache or migraine (past year)
- Significant literacy, visual, or hearing problems
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
There is a credible basis for lateral prefrontal cortex and insula deep repetitive transcranial magnetic stimulation (dTMS) stimulation as a treatment for cannabis use disorder (CUD), but no studies to date have examined this. Evidence of benefit could expand the treatment options available for CUD but require randomized controlled trials (RCTs) to evaluate its efficacy. Toward an RCT of this intervention, the proposed study is a phase 1 open-label pilot trial of dTMS for adults with CUD. This study will establish the viability of an H4 protocol constituting an active arm of a future double-blind RCT.
The group in the trial
- H4 dTMSTreatment being tested
The participants will receive 18 H4 dTMS sessions over 4-6 weeks as an adjunct to evidence-based standard care for CUD (i.e., motivational interviewing and contingency management).
Treatment: dTMS stimulation via the H4 coil
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1 Open-Label Pilot Trial of Deep Repetitive Transcranial Stimulation of the Lateral Prefrontal Cortex and Insula for Adults With Moderate-to-Severe Cannabis Use Disorder
- Publications
- Phase 1 Open-Label Pilot Trial of H4 Deep Repetitive Transcranial Magnetic Stimulation for Adults With Moderate-to-Severe Cannabis Use Disorder.Neuromodulation : journal of the International Neuromodulation Society, 2026
- Record updated
- 30 March 2026